The surge in demand for COVID-19 vaccines has presented lucrative opportunities for both innovators and contract service providers having continuous and semi-continuous manufacturing capabilities for biointensification



Roots Analysis has announced the addition of “Continuous and Semi-Continuous Bioprocessing Market, 2021 – 2030” report to its list of offerings.


Given the growing pipeline of biological drugs, and the rising preference for such therapeutic interventions, the demand for cost-effective biomanufacturing processes has increased. As a result, several innovators and contract service providers are evaluating the potential of continuous and semi-continuous upstream and downstream bioprocessing technologies, owing to their various advantages.


To order this 190+ page report, which features 60+ figures and 115+ tables, please visit this


Key Market Insights


Presently, more than 70 companies claim to have capabilities for continuous manufacturing of biologics

Close to 45% of the continuous and semi-continuous bioprocessing companies are headquartered in Europe; further, around 20% of these companies have established their dedicated facilities in other geographical regions, such as North America and Asia-Pacific.


Over 65% of the installed continuous upstream manufacturing capacity belongs to established players

More than 40% of the global continuous upstream processing capacity is installed in Europe, followed by Asia-Pacific (33%). Further, close to 55% of the capacity belongs to the facilities owned by contract service providers.


Continuous and semi-continuous bio-intensification approach has potential to save ~40% of the overall biopharmaceutical manufacturing cost

By 2030, we expect that adoption of continuous and semi-continuous approach is likely to enable the net, annual cost savings of close to USD 50 billion.


By 2030, the opportunity within the continuous and semi-continuous bioprocessing market is likely to be over USD 500 million

Presently, the use of continuous and semi-continuous bio-intensification approach is largely restricted to the developed nations, and the majority of revenues from biologics manufactured via this approach are distributed between North America (~25%) and Europe (~40%). Once this process is adopted for the end-to-end manufacturing of biologics, estimates in the report suggest are likely to grow at even higher pace.


To request a sample copy / brochure of this report, please visit this


Key Questions Answered

  • Who are the leading contract manufacturers with expertise in continuous and semi-continuous bioprocessing?
  • Who are the leading innovators / drug developers with expertise in continuous and semi-continuous bioprocessing?
  • In which regions are majority of the continuous and semi-continuous bioprocessing facilities located?
  • What is the likely cost saving potential of continuous and semi-continuous bioprocessing technology?
  • What is the currently installed global capacity for continuous and semi-continuous bioprocessing?
  • How is the current and future market opportunity likely to be distributed across key market segments?


The USD 500+ million (by 2030) financial opportunity associated with continuous and semi-continuous bioprocessing services market has been analyzed across the following segments:

  • Type of Manufacturer
  • Innovator / Drug Developer
  • Contract Service Provider


  • Company Size
  • Large
  • Mid-sized
  • Small


  • Scale of Operation
  • Preclinical / Clinical
  • Commercial


  • Stage of Bioprocess
  • Upstream Bioprocessing
  • Downstream Bioprocessing


  • Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • MENA
  • Latin America and Rest of the World



The report also features inputs from eminent industry stakeholders, according to whom, continuous and semi-continuous bioprocessing technologies are likely to witness a significant increase in the adoption rate in the near future, given their advantages over the traditional bioprocessing technologies. The report includes detailed transcripts of discussions held with the following experts:



The research includes profiles of key players (listed below), featuring a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.

  • AGC Biologics
  • Biogen
  • Bristol-Myers Squibb
  • Enzene Biosciences
  • FUJIFLM Diosynth Biotechnologies
  • Merck KGaA
  • Novasep
  • Sanofi Genzyme
  • UCB Pharma
  • WuXi Biologics



For additional details, please visit or email



You may also be interested in the following titles:

  1. Pharmaceutical Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030
  2. Lipid Contract Manufacturing Market: Industry Trends and Global Forecasts, 2021-2030
  3. Biologics Fill / Finish Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
  4. Vaccine Contract Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030


Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Facebook -

LinkedIn -

Twitter -

Medium -

Pinterest -

Quora -